156 related articles for article (PubMed ID: 30538112)
21. SLX4IP acts with SLX4 and XPF-ERCC1 to promote interstrand crosslink repair.
Zhang H; Chen Z; Ye Y; Ye Z; Cao D; Xiong Y; Srivastava M; Feng X; Tang M; Wang C; Tainer JA; Chen J
Nucleic Acids Res; 2019 Nov; 47(19):10181-10201. PubMed ID: 31495888
[TBL] [Abstract][Full Text] [Related]
22. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
Ting S; Mairinger FD; Hager T; Welter S; Eberhardt WE; Wohlschlaeger J; Schmid KW; Christoph DC
Clin Lung Cancer; 2013 Sep; 14(5):558-567.e3. PubMed ID: 23810210
[TBL] [Abstract][Full Text] [Related]
23. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
De Silva IU; McHugh PJ; Clingen PH; Hartley JA
Nucleic Acids Res; 2002 Sep; 30(17):3848-56. PubMed ID: 12202770
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.
Hamilton G; Rath B
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):17-24. PubMed ID: 29226731
[TBL] [Abstract][Full Text] [Related]
25. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.
Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T
Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264
[TBL] [Abstract][Full Text] [Related]
26. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
27. Recruitment and positioning determine the specific role of the XPF-ERCC1 endonuclease in interstrand crosslink repair.
Klein Douwel D; Hoogenboom WS; Boonen RA; Knipscheer P
EMBO J; 2017 Jul; 36(14):2034-2046. PubMed ID: 28292785
[TBL] [Abstract][Full Text] [Related]
28. ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
Papadaki C; Sfakianaki M; Ioannidis G; Lagoudaki E; Trypaki M; Tryfonidis K; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
J Thorac Oncol; 2012 Apr; 7(4):663-71. PubMed ID: 22425915
[TBL] [Abstract][Full Text] [Related]
29. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer.
Weberpals J; Garbuio K; O'Brien A; Clark-Knowles K; Doucette S; Antoniouk O; Goss G; Dimitroulakos J
Int J Cancer; 2009 Feb; 124(4):806-15. PubMed ID: 19035454
[TBL] [Abstract][Full Text] [Related]
30. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
Yu JJ; Lee KB; Mu C; Li Q; Abernathy TV; Bostick-Bruton F; Reed E
Int J Oncol; 2000 Mar; 16(3):555-60. PubMed ID: 10675489
[TBL] [Abstract][Full Text] [Related]
31. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
[TBL] [Abstract][Full Text] [Related]
32. Applications of genomics in NSCLC.
Rosell R; Cobo M; Isla D; Sanchez JM; Taron M; Altavilla G; Santarpia M; Moran T; Catot S; Etxaniz O
Lung Cancer; 2005 Dec; 50 Suppl 2():S33-40. PubMed ID: 16557672
[TBL] [Abstract][Full Text] [Related]
33. Reduced hematopoietic reserves in DNA interstrand crosslink repair-deficient Ercc1-/- mice.
Prasher JM; Lalai AS; Heijmans-Antonissen C; Ploemacher RE; Hoeijmakers JH; Touw IP; Niedernhofer LJ
EMBO J; 2005 Feb; 24(4):861-71. PubMed ID: 15692571
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of nuclear NF-κB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors.
Azambuja AA; Engroff P; Silva BT; Zorzetti RCS; Morrone FB
Int Braz J Urol; 2020; 46(3):353-362. PubMed ID: 32167697
[TBL] [Abstract][Full Text] [Related]
35. CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene.
Liu YC; Chang PY; Chao CC
Nucleic Acids Res; 2015 Dec; 43(22):10760-81. PubMed ID: 26384430
[TBL] [Abstract][Full Text] [Related]
36. ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair.
Stordal B; Davey R
Cancer Chemother Pharmacol; 2009 Mar; 63(4):661-72. PubMed ID: 18575867
[TBL] [Abstract][Full Text] [Related]
37. Double-strand breaks induce homologous recombinational repair of interstrand cross-links via cooperation of MSH2, ERCC1-XPF, REV3, and the Fanconi anemia pathway.
Zhang N; Liu X; Li L; Legerski R
DNA Repair (Amst); 2007 Nov; 6(11):1670-8. PubMed ID: 17669695
[TBL] [Abstract][Full Text] [Related]
38. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
39. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.
Goldberg Z; Evans J; Birrell G; Brown JM
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):175-82. PubMed ID: 11163512
[TBL] [Abstract][Full Text] [Related]
40. Processing of a psoralen DNA interstrand cross-link by XPF-ERCC1 complex in vitro.
Fisher LA; Bessho M; Bessho T
J Biol Chem; 2008 Jan; 283(3):1275-1281. PubMed ID: 18006494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
